mRNA Biodistribution Analysis Service
Overview
The rapid evolution of messenger RNA (mRNA) therapeutics has revolutionized the landscape of modern medicine, particularly in vaccine development and gene therapy. However, the clinical success of these modalities is heavily dependent on their delivery efficiency and precise localization within the body. CD BioGlyco provides a specialized mRNA biodistribution analysis service designed to track the journey of mRNA molecules and their delivery vehicles from the site of administration to target organs and intracellular compartments.
Understanding the pharmacokinetic (PK) profile of mRNA-lipid nanoparticle (LNP) complexes is essential for evaluating both efficacy and safety. Our service utilizes high-sensitivity analytical methods to quantify mRNA concentration, assess tissue accumulation, and determine the duration of protein expression across various biological matrices. By providing a clear map of distribution, we help researchers optimize delivery systems and minimize off-target effects.
Key Technologies
- Polymerase Chain Reaction (PCR)
We utilize quantitative PCR (qPCR) and droplet digital PCR (ddPCR) for the absolute quantification of mRNA copies in various tissues. ddPCR offers unparalleled sensitivity and precision, allowing for the detection of low-abundance transcripts without the need for a standard curve. - In Situ Hybridization (ISH)
To understand spatial distribution at the cellular level, we perform ISH using branched DNA technology. This allows for the visual localization of mRNA within specific tissue architectures, providing insights into which cell types are successfully internalizing the payload.
Precision Mapping of mRNA Disposition for Optimized Therapeutic Outcomes
At CD BioGlyco, our mRNA biodistribution analysis service is an integral part of our broader therapeutic nucleic acid development platform. We provide a holistic analysis that encompasses the following:
- Total and Intact mRNA Quantification
We measure both the total amount of mRNA and the proportion of intact, functional mRNA remaining in circulation or tissues over time. - Multi-Organ Profiling
Systematic analysis of distribution across primary organs (liver, spleen, lungs) and secondary sites (brain, gonads, heart) to identify potential accumulation risks. - Delivery Vehicle Component Tracking
Quantification of lipid components to correlate vehicle stability with mRNA release kinetics. - Reporter Protein Expression Analysis
Bridging the gap between biodistribution and bioactivity by measuring the levels of the encoded protein (e.g., Luciferase) in the same tissue samples.
Workflow
Project Consultation and Design
We begin with a detailed discussion of your project goals, including the mRNA construct, delivery system, and target indication. Our experts help design the study parameters, such as dosing routes, animal models, and sacrifice time points.
Sample Preparation and Labeling
Depending on the detection method, we incorporate specific labels or design highly specific primers and probes for PCR-based detection. We ensure that labeling does not interfere with the natural biodistribution of the LNP-mRNA complex.
Animal Administration and Monitoring
The test articles are administered to the selected animal models. We monitor for any immediate physiological responses and manage the precise timing of sample collection to capture the absorption and distribution phases accurately.
Tissue Collection and Matrix Processing
At designated time points, tissues and biofluids (blood, lymph, urine) are harvested. We use specialized stabilization buffers and ultra-low temperature processing to prevent mRNA degradation by endogenous ribonucleases (RNases).
High-Sensitivity Bioanalysis
Samples are analyzed using our core technologies. This includes mRNA extraction and quantification via ddPCR, lipid extraction for liquid chromatography-mass spectrometry (LC-MS), and tissue sectioning for spatial ISH analysis to confirm cellular uptake.
Data Interpretation and Reporting
Our bioinformatics team processes the raw data to provide a comprehensive pharmacokinetic report. This includes half-life (t1/2) and tissue-to-plasma ratios, accompanied by high-resolution imaging.
Publication Data
DoI: 10.1038/s41541-024-00932-x
Journal: npj Vaccines
IF: 6.9
Published: 2024
This study explores LNP-formulated self-amplifying mRNA (sa-mRNA) vaccines targeting avian influenza. Four vaccines were developed, encoding secreted full-length hemagglutinin (HA), secreted HA head/stalk domains, and membrane-anchored full-length HA. Optimized at an N/P ratio of 10, the vaccines induced robust humoral and cellular immunity in mice, with antibody titers correlating positively with dose. Membrane-anchored full-length HA outperformed secreted versions in eliciting antibodies, mucosal IgA, and T cell responses. Intramuscularly injected sa-mRNA-LNPs were distributed mainly to the injection site, draining lymph nodes, and spleen, with minimal presence in other organs and no major side effects. Even at a low 0.25 µg dose post-boost, protective HA titers were achieved, highlighting the vaccines' potential as a rapid, effective strategy against avian influenza.
Fig.1 The biodistribution of the sa-mRNA-LNP vaccines in mice after intramuscular administration. (Cui, et al., 2024)
Applications
mRNA Vaccine Development
Essential for assessing the duration of mRNA persistence at the injection site versus systemic circulation. This helps in optimizing the dose and ensuring that the vaccine reaches the desired lymphoid tissues.
Protein Replacement Therapy Development
Critical for confirming that mRNA encoding therapeutic enzymes or proteins reaches the target organ and maintains expression levels without causing systemic toxicity.
Cancer Immunotherapy
Used to evaluate the targeting efficiency of mRNA-based cancer vaccines or in situ chimeric antigen receptor (CAR) therapies. Accurate distribution data ensures that the treatment selectively activates the immune system.
Rare Disease Research
Supports the development of gene-editing tools by mapping the delivery of mRNA-encoded nucleases. Precise biodistribution analysis is vital for minimizing off-target editing in non-target tissues.
Advantages
Unrivaled Sensitivity and Precision
By utilizing ddPCR and optimized extraction protocols, we achieve extremely low limits of quantification (LOQ), enabling the detection of mRNA even in tissues with very low accumulation or high clearance rates.
Comprehensive Multi-Component Tracking
Unlike standard services, we track the mRNA payload, the lipid carrier components, and the resulting protein expression simultaneously, providing a truly holistic view.
Expert Scientific Consultation
Our team of PhD-level scientists provides proactive guidance on study design and data interpretation, helping you troubleshoot delivery challenges.
Advanced Spatial Resolution
Our ISH capabilities allow you to see exactly where your mRNA is acting at the cellular level, moving beyond bulk tissue homogenization to provide nuanced insights into cellular targeting and endosomal escape.
Frequently Asked Questions
Customer Review
The team at CD BioGlyco provided exceptional support for our mRNA vaccine candidate. Their ability to track both the mRNA and the ionizable lipid allowed us to identify a key stability issue in the spleen that we had previously missed.
— C.T., Biopharmaceutical Company
The ddPCR results were highly reproducible, and the ISH imaging provided the spatial context we needed to prove our LNP was successfully targeting hepatocytes.
— E.T., Innovative Gene Therapy Startup
We were impressed by the technical depth and the regulatory focus of the reports. Their commitment to quality is evident in every step.
— Q.T., Vaccine Research Institute
Associated Services
CD BioGlyco provides a world-class mRNA biodistribution analysis service that combines high-sensitivity quantification, spatial localization, and multi-component tracking. Please feel free to contact us for detailed information on our services or to request a formal quotation.
Reference
- Cui, X.; et al. Immunogenicity and biodistribution of lipid nanoparticle formulated self-amplifying mRNA vaccines against H5 avian influenza. npj Vaccines. 2024, 9: 138. (Open Access)